| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | QL-XI-92 | GDSC1000 | pan-cancer | AAC | -0.0025 | 0.9 |
| mRNA | ABT-263 | CTRPv2 | pan-cancer | AAC | -0.0028 | 0.9 |
| mRNA | triazolothiadiazine | CTRPv2 | pan-cancer | AAC | -0.0024 | 0.9 |
| mRNA | QS11 | GDSC1000 | pan-cancer | AAC | -0.0027 | 0.9 |
| mRNA | SJ-172550 | CTRPv2 | pan-cancer | AAC | -0.0029 | 0.9 |
| mRNA | BRD-K92856060 | CTRPv2 | pan-cancer | AAC | -0.0027 | 0.9 |
| mRNA | parbendazole | CTRPv2 | pan-cancer | AAC | 0.0023 | 0.9 |
| mRNA | AP-24534 | GDSC1000 | pan-cancer | AAC | -0.0024 | 0.9 |
| mRNA | CD-437 | CTRPv2 | pan-cancer | AAC | -0.0023 | 0.9 |
| mRNA | SNX-2112:bortezomib (250:1 mol/mol) | CTRPv2 | pan-cancer | AAC | -0.0022 | 0.9 |